Run In Medication

Phase 3Small molecule

GSK

Run In Medication is one of 31 small molecule programs targeting Nasal polyposis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasal PolyposisActive, not recruiting

AsthmaActive, not recruiting

Nasal PolyposisPhase 2

Active, not recruiting

AsthmaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Singulair

AstraZeneca

Preclinical

17 2

Run In Medication

GSK

Phase 3

1 3

Spiriva

Boehringer Ingelheim

Preclinical

8 4

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 5

Arcoxia

Symbicort

6 7

Atrovent

Boehringer Ingelheim

Preclinical

2 8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

1 9

Paracetamol

GSK

Preclinical

1 10

Aclidinium Bromide

AstraZeneca

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Not yet recruiting

Asthma

NCT05776927

Clinical

Trials by Indication[1]

Asthma1 trial

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Not yet recruiting· Novartis logo

Novartis·Phase 3·NCT05776927·304 enrolled

Nasal polyposis1 trial

Mepolizumab in Nasal Polyposis

Completed· GSK logo

GSK·Phase 2·NCT01362244·109 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Run In Medication. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Run In Medication compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Run In Medication. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Run In Medication

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Asthma1 trial

Nasal polyposis1 trial

References

Drug Info

Quick Facts

Related News